Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pneumothorax II: Pathophysiology

Pneumothorax II: Pathophysiology

Pneumothorax means the presence of air in the pleural space — the thin potential gap between the visceral and parietal pleura. This condition disrupts the normal pressure balance that keeps the lungs inflated, leading to partial or complete collapse of the affected lung.Normal physiologyUnder normal conditions, the pleural space maintains a slightly negative intrapleural pressure, which keeps the lungs expanded against the chest wall. This negative pressure creates a delicate balance between...

Asthma III: Clinical Manifestations

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026

Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026

Same author

Premature hair greying in patients with pulmonary fibrosis and relatives is suggestive of pathogenic variants in telomere related genes.

The European respiratory journal·2026

Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026

Same author

Behavioural changes in exposure patterns after genetic counselling among asymptomatic first-degree relatives of patients with pulmonary fibrosis and carriers of a telomere-related gene variant.

ERJ open research·2026

Same author

Considering molecular pharmacology for sarcoidosis treatment.

The Lancet. Respiratory medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

[Thoracic sarcoidosis].

Hilario Nunes¹, Yurdagul Uzunhan, Olivia Freynet

¹Université Paris 13, EA2363, AP-HP, Hôpital Avicenne, Service de pneumologie, F-93000 Bobigny, France. hilario.nunes@avc.aphp.fr

Presse Medicale (Paris, France : 1983)

|December 5, 2009

Summary

This summary is machine-generated.

Sarcoidosis commonly affects the lungs, with diagnosis relying on clinical history, imaging, and granulomas. Systemic corticosteroids are the primary treatment for thoracic sarcoidosis requiring intervention.

More Related Videos

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Area of Science:

Pulmonary Medicine
Immunology
Radiology

Background:

Sarcoidosis frequently involves the thorax (lungs/mediastinum) in ~90% of patients, either isolated or with extrathoracic sites.
Diagnosis requires compatible clinical/radiologic findings, noncaseous granulomas, and exclusion of other granulomatous diseases.
Radiographic staging is crucial for prognosis, with pulmonary fibrosis and hypertension being major causes of morbidity/mortality.

Purpose of the Study:

To outline the diagnostic criteria and prognostic indicators for thoracic sarcoidosis.
To detail the indications for systemic treatment in sarcoidosis.
To highlight the established treatment modalities for thoracic sarcoidosis.

Main Methods:

Review of clinical, radiologic, and histopathologic diagnostic criteria for sarcoidosis.
Analysis of prognostic factors, including radiographic staging and complications like pulmonary fibrosis.
Evaluation of treatment indications and the role of systemic corticosteroid therapy.

Main Results:

Diagnosis is clinical/radiologic, with biopsy not always required (e.g., Löfgren syndrome, stage progression).
Radiographic stage significantly impacts prognosis; pulmonary fibrosis is a key determinant of outcomes.
Approximately 50% of patients recover spontaneously; the other 50% require systemic treatment.
Treatment is indicated for symptomatic advanced disease, persistent activity, or specific bronchial involvements.
Systemic corticosteroids are the standard treatment for thoracic sarcoidosis.

Conclusions:

Thoracic sarcoidosis diagnosis and staging are critical for prognosis and treatment decisions.
Pulmonary fibrosis and hypertension significantly influence patient outcomes.
Systemic corticosteroid therapy remains the cornerstone treatment for managing thoracic sarcoidosis.